RS62465B1 - Imatinib za upotrebu u lečenju moždanog udara - Google Patents

Imatinib za upotrebu u lečenju moždanog udara

Info

Publication number
RS62465B1
RS62465B1 RS20211286A RSP20211286A RS62465B1 RS 62465 B1 RS62465 B1 RS 62465B1 RS 20211286 A RS20211286 A RS 20211286A RS P20211286 A RSP20211286 A RS P20211286A RS 62465 B1 RS62465 B1 RS 62465B1
Authority
RS
Serbia
Prior art keywords
imatinib
stroke
treatment
Prior art date
Application number
RS20211286A
Other languages
English (en)
Inventor
Ulf Eriksson
Nils Gunnar Wahlgren
Original Assignee
Hamra Invest Ab
Brain Consultant Nils Gunnar Wahlgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamra Invest Ab, Brain Consultant Nils Gunnar Wahlgren Ab filed Critical Hamra Invest Ab
Publication of RS62465B1 publication Critical patent/RS62465B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20211286A 2016-02-29 2017-02-27 Imatinib za upotrebu u lečenju moždanog udara RS62465B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke
PCT/SE2017/050183 WO2017151043A1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke
EP17760399.0A EP3423060B1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke

Publications (1)

Publication Number Publication Date
RS62465B1 true RS62465B1 (sr) 2021-11-30

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211286A RS62465B1 (sr) 2016-02-29 2017-02-27 Imatinib za upotrebu u lečenju moždanog udara

Country Status (17)

Country Link
US (2) US10953010B2 (sr)
EP (1) EP3423060B1 (sr)
JP (1) JP6914957B2 (sr)
CN (1) CN108697711A (sr)
AU (1) AU2017227515B2 (sr)
DK (1) DK3423060T3 (sr)
ES (1) ES2895432T3 (sr)
HR (1) HRP20211621T1 (sr)
HU (1) HUE056798T2 (sr)
LT (1) LT3423060T (sr)
PL (1) PL3423060T3 (sr)
PT (1) PT3423060T (sr)
RS (1) RS62465B1 (sr)
RU (1) RU2739382C1 (sr)
SE (1) SE539450C2 (sr)
SI (1) SI3423060T1 (sr)
WO (1) WO2017151043A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
WO2023086768A1 (en) * 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
WO2024057296A2 (en) 2023-06-28 2024-03-21 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and a process for preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2007124308A2 (en) 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
US20100136094A1 (en) 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
EP2411028B9 (en) * 2009-03-27 2019-11-20 Moleac Pte Ltd. Therapy for promoting cell growth

Also Published As

Publication number Publication date
LT3423060T (lt) 2021-11-10
HUE056798T2 (hu) 2022-03-28
SE1650260A1 (en) 2017-08-30
ES2895432T3 (es) 2022-02-21
EP3423060A1 (en) 2019-01-09
HRP20211621T1 (hr) 2022-02-04
WO2017151043A1 (en) 2017-09-08
SI3423060T1 (sl) 2021-11-30
EP3423060B1 (en) 2021-07-21
JP6914957B2 (ja) 2021-08-04
SE539450C2 (en) 2017-09-26
US10953010B2 (en) 2021-03-23
EP3423060A4 (en) 2020-01-01
US20190030030A1 (en) 2019-01-31
PL3423060T3 (pl) 2022-01-10
AU2017227515B2 (en) 2022-03-24
US20210236488A1 (en) 2021-08-05
DK3423060T3 (da) 2021-10-25
AU2017227515A1 (en) 2018-08-30
PT3423060T (pt) 2021-10-20
RU2739382C1 (ru) 2020-12-23
CN108697711A (zh) 2018-10-23
JP2019507165A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
HK1252645A1 (zh) 按摩機
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
GB201608885D0 (en) Treatment
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
GB201608797D0 (en) Therapeutic use
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
HK1256164A1 (zh) 用於治療神經膠質瘤的製劑
RS64798B1 (sr) Upotreba delgocitiniba za lečenje hroničnog ekcema šaka
IL272658A (en) Surface treatment
RS65009B1 (sr) Sastav za upotrebu u lečenju crevnih promena
PL3303486T3 (pl) Kompozycja do obróbki powierzchni
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB2551906B (en) Body component
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
TWM534166U (en) Can body
GB201511772D0 (en) Improvements in the treatment of ash